Ambient Biosciences

About Ambient Biosciences

Ambient Biosciences, formerly Upkara, is a pioneering company in the biopreservation sector, aiming to revolutionize the way therapeutics, vaccines, and reagents are stored and transported. By eliminating the need for cold chain logistics, Ambient Biosciences addresses a significant pain point in the pharmaceutical industry, which faces an estimated $16 billion in annual losses due to cold chain failures. The company's patented technology seamlessly integrates with existing FDA-approved excipients and lyophilization methods, making it readily scalable with minimal reagent and capital equipment requirements.

Ambient Biosciences's technology is designed to be more resource-efficient and offers superior preservation compared to traditional methods. This innovation is particularly crucial in a market where medical pharmaceutical refrigeration costs are projected to reach $18.6 billion in 2022. Furthermore, the technology has broad applications, including the biopreservation of biologics, vaccines, nucleic acids, and blood products.

The company primarily serves pharmaceutical companies, biotech firms, and healthcare providers, offering them a more reliable and cost-effective solution for biopreservation. Ambient Biosciences's business model revolves around licensing its technology and providing biopreservation services, thereby generating revenue through both upfront fees and ongoing royalties.

In summary, Ambient Biosciences is positioned to make a significant impact on the pharmaceutical supply chain by reducing costs and improving the reliability of biopreservation. This is particularly important in addressing global health challenges, such as the 20 million children who remain unvaccinated and the 1.5 million under the age of five who die from vaccine-preventable diseases each year.